Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. 1996

C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
Department of Medicine, Christchurch Hospital, New Zealand.

Although many studies have examined the effects of administering natriuretic peptide receptor C (NPR-C) ligands and endopeptidase 24.11 (EP 24.11) inhibitors on clearance and bioactivity of atrial natriuretic peptide (ANP), none have systematically compared their effects on the endogenous levels of both ANP and brain natriuretic peptide (BNP) under physiological conditions. Accordingly, we examined the hemodynamic, hormonal, and renal actions of an EP 24.11 inhibitor, SCH-32615, and an NPR-C ligand, C-ANP-(4-23), both alone and in combination in eight normal conscious sheep. NPR-C blockade and EP 24.11 inhibition induce similar rises in plasma ANP, BNP, and guanosine 3',5'-cyclic monophosphate (cGMP). Synergistic increments in plasma ANP, BNP, and cGMP observed during combined administration are likely to be due to the reduced clearance of C-ANP-(4-23) in the setting of EP 24.11 inhibition, leading to increased inhibition of the receptor pathway. Combined administration was also associated with enhanced hemodynamic actions and diuretic and natriuretic effects. Our findings show that both enzymatic and receptor clearance pathways contribute equally to natriuretic peptide clearance and induce potentially important hemodynamic and renal effects in normal conscious sheep.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004231 Diuresis An increase in the excretion of URINE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Diureses
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic

Related Publications

C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
March 1991, The Journal of pharmacology and experimental therapeutics,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
May 1988, FEBS letters,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
September 1993, British journal of pharmacology,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
August 1993, Hypertension (Dallas, Tex. : 1979),
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
June 1991, The American journal of physiology,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
January 1986, Biomedica biochimica acta,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
November 1990, Biochemical and biophysical research communications,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
February 1985, Biochemical Society transactions,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
September 1989, Journal of cardiovascular pharmacology,
C J Charles, and E A Espiner, and M G Nicholls, and A M Richards, and T G Yandle, and A Protter, and T Kosoglou
June 1991, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!